CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 992273-992517 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T58382","span":{"begin":0,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"One MS patient with high circulating levels of opsonizing antimyelin antibodies and severe progressive spinal cord involvement refractory to intravenous methylprednisolone and glatiramer acetate improved following B cell depletion by rituximab."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T313","span":{"begin":0,"end":244},"obj":"Sentence"}],"text":"One MS patient with high circulating levels of opsonizing antimyelin antibodies and severe progressive spinal cord involvement refractory to intravenous methylprednisolone and glatiramer acetate improved following B cell depletion by rituximab."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T3044","span":{"begin":103,"end":114},"obj":"Body_part"}],"attributes":[{"id":"A3044","pred":"uberon_id","subj":"T3044","obj":"http://purl.obolibrary.org/obo/UBERON_0002240"}],"text":"One MS patient with high circulating levels of opsonizing antimyelin antibodies and severe progressive spinal cord involvement refractory to intravenous methylprednisolone and glatiramer acetate improved following B cell depletion by rituximab."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T6137","span":{"begin":4,"end":6},"obj":"Disease"},{"id":"T94060","span":{"begin":4,"end":6},"obj":"Disease"}],"attributes":[{"id":"A6137","pred":"mondo_id","subj":"T6137","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A95116","pred":"mondo_id","subj":"T94060","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"One MS patient with high circulating levels of opsonizing antimyelin antibodies and severe progressive spinal cord involvement refractory to intravenous methylprednisolone and glatiramer acetate improved following B cell depletion by rituximab."}